BAYRY's Eylea 8 mg gets CHMP nod in EU, promising 6-month dosing for nAMD and DME with strong 3-year efficacy and safety data ...

Bayer’s retinal disease treatment Eylea (aflibercept) is set for an extended treatment interval, a label extension that could give the drug an advantage over rival Roche’s Vabysmo (faricimab). A ...

German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

Berlin: Bayer has received approval from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for Eylea 8 mg (aflibercept 8 mg) for the treatment ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Bayer A.G. ( OTCPK:BAYZF) ( OTCPK:BAYRY) said that an advisory panel of the European Medicines Agency (EMA), endorsed the ...

Bayer announces EMA committee recommends label extension approval for Eylea 8 mg: Berlin Monday, May 26, 2025, 17:00 Hrs [IST] Bayer announced that the Committee for Medicinal Pro ...

China’s NMPA approves Eylea 8 mg for wet age-related macular degeneration: Berlin Friday, May 23, 2025, 09:00 Hrs [IST] The Center for Drug Evaluation (CDE) of China’s Nationa ...

At ARVO 2025, in Salt Lake City, Utah, Dilsher Dhoot, MD, FASRS, and Mark Barakat, MD, talked about the PHOTON trial, 8 mg ...

Bayer said in a statement the European Medicines Agency recommended that eye drug Eylea, at a high dose of 8 mg, can be injected at intervals of up to six months to treat wet age-related macular ...

The Retina World Congress showcases global innovations in surgical and medical retina, highlighting emerging treatments and ...